Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution

Background Global data demonstrate minimal improvement in the survival rate for oral cavity cancer (OCC) patients. We wished to know whether or not clinical features and survival rate have changed over time for OCC patients receiving initial treatment and follow-up at a large cancer center in China. Methods Clinical features and survival data were collected on patients diagnosed during the successive decades of 1960–1969 (n=253), 1970–1979 (n=497), 1980–1989 (n= 659), 1990–1999 (n=793), and 2000–2009 (n=1,160) at the Sun Yat-sen University Cancer Center. Results Over time, the overall 5-year survival rate for OCC patients was 52.0%. According to tumor localization, this rate was 71.4% for lip cancer, 56.3% for oral tongue cancer, and 42.7% for other parts of the oral cavity. From the 1960s to the 2000s, the 5-year survival rate steadily improved from 47.8% to 55.6% (P<0.001). Survival steadily decreased with age and was higher for women than for men in the 3 most recent decades. The survival rate for male patients was constant over time, while the rate for female patients improved dramatically. Obvious trends in clinical features over time included the following: increasing age of patients, increasing proportions of localized disease at diagnosis, decreasing proportions of diagnoses of lip cancer, decreasing proportions of diagnoses of squamous cell carcinoma, and decreasing proportions of non-surgical treatment approaches. Conclusion The survival rate has steadily improved for OCC patients at this cancer center.

[1]  W. Chiang,et al.  Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan. , 2010, Oral oncology.

[2]  R. Corvò,et al.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Decker,et al.  Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  Huan Li,et al.  Epidemiologic characteristics of oral cancer: single-center analysis of 4097 patients from the Sun Yat-sen University Cancer Center , 2016, Chinese journal of cancer.

[6]  K. Omura Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma , 2014, International Journal of Clinical Oncology.

[7]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[8]  G. Pringle,et al.  Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. , 2007, Oral oncology.

[9]  N. Bhattacharyya,et al.  Survival in oral cavity minor salivary gland carcinoma , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  S. Warnakulasuriya Global epidemiology of oral and oropharyngeal cancer. , 2009, Oral oncology.

[11]  K. Roberts-Thomson,et al.  Epidemiology of oral cancer in Asia in the past decade--an update (2000-2012). , 2013, Asian Pacific journal of cancer prevention : APJCP.

[12]  Mike Quinn,et al.  Standard cancer patient population for age standardising survival ratios. , 2004, European journal of cancer.

[13]  Hutcha Sriplung,et al.  Cancer survival in Africa, Asia, and Central America: a population-based study. , 2010, The Lancet. Oncology.

[14]  Jonathan R. Clark,et al.  Concurrent chemoradiotherapy compared with surgery and adjuvant radiotherapy for oral cavity squamous cell carcinoma , 2015, Head & neck.

[15]  E. Vokes,et al.  Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jacques Ferlay,et al.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[18]  K. Soo,et al.  Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10‐year update and subset analysis , 2015, Cancer.

[19]  M. Fujii Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer , 2014, International Journal of Clinical Oncology.

[20]  Stefan Listl,et al.  Survival of Patients with Oral Cavity Cancer in Germany , 2013, PloS one.

[21]  A. Carvalho,et al.  Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives. , 2015, Oral oncology.

[22]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[23]  D F Wilson,et al.  The epidemiology of tongue cancer: a review of global incidence. , 2008, Oral diseases.